Outcomes and Assessments
Cross-source consensus on Outcomes and Assessments from 1 sources and 7 claims.
1 sources · 7 claims
Other
Other
Other
Highlighted claims
- Follow-up visits occur at weeks 4, 12, 24, 36, and 48. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- The primary endpoint is complete resolution of subfoveal fluid at week 12. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- Primary endpoint assessment is performed by site investigators without a central reading centre. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- Secondary endpoints include complete resolution of central macular detachment at weeks 24, 36, and 48. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- Secondary endpoints include stable or improved BCVA at weeks 12, 24, 36, and 48. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- FA/ICGA is performed at baseline and week 48. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- Secondary endpoints include macular neovascularisation incidence and recurrence rate after initial resolution over 48 weeks. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial